Drug intelligence / Profile preview

AP-161

Development stage: Preclinical
Lead developer: Alphageneron
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

AP-161 is an allogenic targeted natural killer (NK) cell therapy in development for the treatment of tumors that express the membrane protein mHsp70. The therapy is designed to target and destroy cancer cells presenting this specific stress-induced protein on their surface. AP-161 is being developed by Alphageneron and represents a form of cell-based immunotherapy aimed at enhancing anti-tumor immune responses.

Targets

HSP70 (Heat shock protein 70)

Beyond the preview

Go deeper on AP-161.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AP-161.

Explore the full profile